Enhanced antiangiogenic therapy with antibody-collagen XVIII NC1 domain fusion proteins engineered to exploit matrix...

Area of Science:

• Oncology
• Biotechnology
• Molecular Biology

Background:

• Antiangiogenic therapy is a key area in cancer research, targeting tumor vascularization.
• Tumor extracellular matrix interactions are critical in regulating angiogenesis.
• Current therapies can be enhanced by leveraging tumor-specific molecular processes.

Purpose of the Study:

• To develop a novel strategy for enhancing antibody-based antiangiogenic cancer therapy.
• To utilize tumor proteolysis of collagen XVIII to release endogenous angiogenesis inhibitors.
• To create a multispecific agent combining an antiangiogenic antibody with endostatin.

Main Methods:

• Fusing the collagen XVIII NC1 domain to an antiangiogenic single-chain antibody.
• Generating a single molecular entity for secretion by gene-modified cells.
• Assessing the processing of the agent by tumor-associated proteinases.
• Evaluating the combined antiangiogenic effects in the tumor microenvironment.

Main Results:

• A multispecific agent was successfully generated, releasing endostatin and functional antibody fragments.
• Tumor-associated proteinases processed the agent, producing complementary antiangiogenic molecules.
• The combined action of these agents led to enhanced antitumor effects.
• Gene-modified cells secreting the agent demonstrated improved therapeutic efficacy.

Conclusions:

• Tailoring recombinant antibodies with extracellular matrix-derived scaffolds is a viable strategy.
• This approach converts tumor progression processes into therapeutic advantages.
• The developed multispecific agent offers a promising new direction for antiangiogenic cancer therapy.